Companies Dominating the Dendritic Cell Cancer Vaccine Landscape
- Kite Pharma
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Argos Therapeutics
- Dendreon
- GlaxoSmithKline
- Batavia Biosciences
- ImmunoCellular Therapeutics Ltd.
- Elios Therapeutics
- Merck & Co.
- Tella Incorporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of dendritic cell cancer vaccine is evaluated at USD 805.27 million.
Dendritic Cell Cancer Vaccine Market size was over USD 730.17 million in 2024 and is poised to exceed USD 3.22 billion by 2037, witnessing over 12.1% CAGR during the forecast period i.e., between 2025-2037.
North America industry is predicted to account for largest revenue share by 2037, as people in the region are more aware and the diagnosis techniques are supreme in these areas.
The major players in the market are Kite Pharma, Argos Therapeutics, Dendreon, GlaxoSmithKline, Batavia Biosciences, ImmunoCellular Therapeutics Ltd., Elios Therapeutics, Merck & Co., Tella Incorporation, and others.
